Skip to main content
NovaBay Pharmaceuticals, Inc. logo

NovaBay Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · NBY ISIN · US66987P2011 LEI · 549300D5U7PQPNEX8Q38 US Manufacturing
Open in API
Filings indexed 1,026 across all filing types
Latest filing 2025-10-09 Board/Management Inform…
Country US United States of America
Listing US NBY

About NovaBay Pharmaceuticals, Inc.

https://novabay.com/

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes scientifically-created and clinically-proven products for the eyecare, skincare, and wound care markets. The company's core technology is a proprietary, stable formulation of hypochlorous acid. Its leading product is Avenova®, an antimicrobial lid and lash solution available over-the-counter for eye hygiene. In the wound care sector, NovaBay manufactures and sells products under the NeutroPhase® and PhaseOne® brands, which utilize its hypochlorous acid technology to aid in cleansing and debridement. The company focuses on providing accessible, problem-solving solutions for improved well-being.

Recent filings

Filing Released Lang Actions
DEFA14A
Board/Management Information Classification · 95% confidence The document contains a Schedule 14A proxy statement and a Form 8-K current report. The key content includes the resignation of a CEO and director, and details about a Securities Purchase Agreement involving preferred stock transfers and shareholder approval at an upcoming Annual Meeting. The document is primarily about management changes and related transactions, not a full annual report or proxy solicitation materials alone. The presence of Item 5.02 (Departure of Directors or Certain Officers) and the detailed description of management changes and related securities transactions indicate this is a Board/Management Information filing. The document length (6928 characters) and detailed content support this classification rather than a brief announcement or proxy solicitation. Therefore, the filing type is MANG (Board/Management Information).
2025-10-09 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes the resignation of a CEO and director, details about a Securities Purchase Agreement involving transfer of preferred stock, and related shareholder approval matters. These topics correspond to changes in senior management and significant corporate transactions. The document is not a full financial report, earnings release, or proxy statement, but rather a regulatory announcement of management changes and capital transaction events. Therefore, the most appropriate classification is 'MANG' for Board/Management Information, as it primarily announces changes in the company's board and senior management along with related capital transaction details. The document length and detail support this classification with high confidence.
2025-10-09 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by NovaBay Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale to the public. The text includes details about the securities to be offered, the shelf registration process, and disclaimers about the prospectus and supplements. This type of filing is related to capital raising and financing activities, specifically the registration of securities for offering. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the registration statement itself, not just an announcement or a certification, so it is not RPA or RNS. Confidence is high given the clear identification of the form and its purpose.
2025-10-03 English
DEF 14A
Proxy Solicitation & Information Statement
2025-09-23 English
ARS
Annual Report
2025-09-23 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes an announcement about a special cash dividend payment and details about the trading of the company's common stock with due bills during the dividend right period. The document also references a press release as an exhibit. The content is an update on a capital event (special dividend) and related trading procedures, which fits the category of Capital/Financing Update. The document length is 4779 characters, which is sufficient to contain substantive information rather than just a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-09-18 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.